4‐Methylumbelliferone Sensitizes Breast Cancer Spheroids to Chemotherapeutic Treatment With Epirubicin: New Perspectives for Pharmacological Repositioning
IUBMB Life · 2025
DOI: 10.1002/iub.70075 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Daiana Luján Vitale und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Microambiente Tumoral - Centro de Investigaciones Básicas y Aplicadas (CIBA) - Universidad Nacional del Noroeste de la Provincia de Bu…. Hauptthemen laut MEDLINE: Breast Neoplasms, Hymecromone, Spheroids, Cellular, Epirubicin. Die Arbeit nennt 80 Literaturangaben. Gefördert von: Universidad Nacional del Noroeste de la Provincia de Buenos Aires, HORIZON-MSCA-2021-SE-01, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación.
Abstract (Originalsprache)
Chemoresistance remains a significant hurdle in breast cancer treatment. To address this, we explored the therapeutic potential of combining epirubicin, an anthracycline commonly associated with the development of resistance in cancer cells and with known cytotoxic effects, with 4‐methylumbelliferone, a plant‐derived coumarin. Our results demonstrated a coactive enhancement of epirubicin efficacy when this combination was applied to 3D breast cancer models, irrespective of molecular subtype. Mechanistically, 4‐methylumbelliferone inhibits synthesis of hyaluronan, a key component of the tumor microenvironment that promotes tumor growth and metastasis. By disrupting hyaluronan production, this compound facilitated drug penetration into tumor spheroids and reduced the expression of drug efflux pumps, thereby increasing intracellular drug accumulation. Consequently, the combined treatment led to a significant reduction in cell viability and promotion of cell death. Our findings suggest that targeting hyaluronan metabolism in conjunction with conventional chemotherapy offers a promising strategy to overcome drug resistance in breast cancer. This drug repositioning approach not only improves treatment efficacy but also highlights the potential of targeting the tumor microenvironment to enhance cancer therapy. Further studies are warranted to elucidate the underlying mechanisms and to evaluate the clinical translation of this combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Microambiente Tumoral - Centro de Investigaciones Básicas y Aplicadas (CIBA) - Universidad Nacional del Noroeste de la Provincia de Buenos Aires, Junín, Argentina.
- Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires (CITNOBA) - UNNOBA-UNSAdA-CONICET, Junín, Argentina.
ORCID-Profile: Daiana Luján Vitale, Laura Daniela Alaniz
Förderung
- Universidad Nacional del Noroeste de la Provincia de Buenos Aires
- HORIZON-MSCA-2021-SE-01
- Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
Zitieren
APA
Vitale, D. L., Icardi, A., Rosales, P., Morán, C., Sevic, I., & Alaniz, L. D. (2025). 4‐Methylumbelliferone Sensitizes Breast Cancer Spheroids to Chemotherapeutic Treatment With Epirubicin: New Perspectives for Pharmacological Repositioning. IUBMB Life. https://doi.org/10.1002/iub.70075
Vancouver
Vitale DL, Icardi A, Rosales P, Morán C, Sevic I, Alaniz LD. 4‐Methylumbelliferone Sensitizes Breast Cancer Spheroids to Chemotherapeutic Treatment With Epirubicin: New Perspectives for Pharmacological Repositioning. IUBMB Life. 2025. doi:10.1002/iub.70075
BibTeX
@article{Vitale2025,
author = {Vitale, Daiana Luján and Icardi, Antonella and Rosales, Paolo and Morán, Candela and Sevic, Ina and Alaniz, Laura Daniela},
title = {4‐Methylumbelliferone Sensitizes Breast Cancer Spheroids to Chemotherapeutic Treatment With Epirubicin: New Perspectives for Pharmacological Repositioning},
journal = {IUBMB Life},
year = {2025},
doi = {10.1002/iub.70075}
}
EUVIMED